Han J H, Van Deerlin V M, Tollefsen D M
Department of Internal Medicine, Washington University, St. Louis, Missouri 63110, USA.
J Biol Chem. 1997 Mar 28;272(13):8243-9. doi: 10.1074/jbc.272.13.8243.
Heparin cofactor II (HCII) inhibits thrombin by forming a stable 1:1 complex. Heparin and dermatan sulfate increase the rate of complex formation >/=1000-fold. Mutation of leucine 444 to arginine at the P1 position of recombinant HCII (rHCII) increases the rate of inhibition of thrombin approximately 100-fold in the absence of a glycosaminoglycan (Derechin, V. M., Blinder, M. A., and Tollefsen, D. M. (1990) J. Biol. Chem. 265, 5623-5628). We now report that heparin facilitates dissociation of the thrombin-rHCII(L444R) complex. In the presence of heparin, thrombin is inhibited rapidly and completely by a 35-fold molar excess of rHCII(L444R), but subsequently approximately 50% of the thrombin activity reappears with a t1/2 of approximately 20 min. At higher ratios of rHCII(L444R) to thrombin, the reappearance of thrombin activity is delayed and the final plateau of activity is decreased. Electrophoretic analysis indicates that proteolysis of excess rHCII(L444R) precedes the reappearance of thrombin activity. Addition of heparin at longer intervals after formation of the thrombin-rHCII(L444R) complex causes a progressive decrease in the thrombin plateau, suggesting that in the absence of heparin the complex is slowly converted to a non-dissociable form. By contrast to heparin, dermatan sulfate does not facilitate dissociation of the thrombin-rHCII(L444R) complex. Our findings indicate that the P1 residue of HCII affects not only the rate of inhibition of thrombin but also the stability of the resulting complex.
肝素辅因子II(HCII)通过形成稳定的1:1复合物来抑制凝血酶。肝素和硫酸皮肤素可使复合物形成速率提高≥1000倍。重组HCII(rHCII)P1位的亮氨酸444突变为精氨酸后,在没有糖胺聚糖的情况下,对凝血酶的抑制速率提高了约100倍(德雷钦,V.M.,布林德,M.A.,和托勒夫森,D.M.(1990年)《生物化学杂志》265,5623 - 5628)。我们现在报告,肝素可促进凝血酶 - rHCII(L444R)复合物的解离。在肝素存在的情况下,凝血酶可被35倍摩尔过量的rHCII(L444R)迅速且完全抑制,但随后约50%的凝血酶活性会重新出现,半衰期约为20分钟。当rHCII(L444R)与凝血酶的比例更高时,凝血酶活性的重新出现会延迟,且最终活性平台会降低。电泳分析表明,过量rHCII(L444R)的蛋白水解先于凝血酶活性的重新出现。在凝血酶 - rHCII(L444R)复合物形成较长时间后添加肝素,会导致凝血酶活性平台逐渐降低,这表明在没有肝素的情况下,复合物会缓慢转化为不可解离的形式。与肝素不同,硫酸皮肤素不会促进凝血酶 - rHCII(L444R)复合物的解离。我们的研究结果表明,HCII的P1残基不仅影响凝血酶的抑制速率,还影响所得复合物的稳定性。